{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:14:08Z","timestamp":1789233248861,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.msard.2022.103792","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T12:18:19Z","timestamp":1649247499000},"page":"103792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in Canada: A descriptive analysis of real-world data"],"prefix":"10.1016","volume":"62","author":[{"given":"Victor","family":"Gitman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aphrodite","family":"Stavropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Pasquarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusanka","family":"Zecevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Devonshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103792_bib0018","unstructured":"Bove R., et\u00a0al. B-Cell levels and immunity in breastfed infants of women with MS treated with ocrelizumab: design of a Phase 4 study (SOPRANINO). Poster presented at ECTRIMS 2021 (P686)."},{"issue":"2","key":"10.1016\/j.msard.2022.103792_bib0027","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/jwh.2020.8860","article-title":"Clinical outcomes in high-risk pregnancies due to advanced maternal age","volume":"30","author":"Correa-de-Araujo","year":"2021","journal-title":"J. Womens Health"},{"issue":"3","key":"10.1016\/j.msard.2022.103792_bib0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/WCO.0000000000000922","article-title":"Use of disease-modifying drugs during pregnancy and breastfeeding","volume":"34","author":"Dobson","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2022.103792_bib0020","unstructured":"Dobson, R., et\u00a0al. Pregnancy and infant outcomes in women receiving ocrelizumab for the treatment of multiple sclerosis. Poster presented at ECTIMS 2021 (P641)."},{"issue":"2","key":"10.1016\/j.msard.2022.103792_bib0006","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","article-title":"Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study","volume":"21","author":"Ebrahimi","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103792_bib0026","unstructured":"European Medicines Agency. Guideline on the exposure to medicinal products during pregnancy, 2005."},{"issue":"1","key":"10.1016\/j.msard.2022.103792_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0029-7844(96)00427-9","article-title":"Causes of fetal death in women of advanced maternal age","volume":"89","author":"Fretts","year":"1997","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.msard.2022.103792_bib0030","article-title":"Pregnancy outcomes after exposure to fingolimod and in the general population","author":"Geissb\u00fchler","year":"2015","journal-title":"ECTRIMS"},{"key":"10.1016\/j.msard.2022.103792_bib0012","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","author":"Gibiansky","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.msard.2022.103792_bib0015","first-page":"84","article-title":"Placental structure, function and drug transfer","volume":"15","author":"Griffiths","year":"2015","journal-title":"BJA Educ."},{"issue":"17","key":"10.1016\/j.msard.2022.103792_bib0010","first-page":"1694","article-title":"Ocrelizumab in primary progressive and relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103792_bib0017","unstructured":"Hellwig K., et\u00a0al. Rationale and design of a Phase 4 study exploring B-cell levels and immune responses in infants born to women with MS who were exposed to ocrelizumab up to 6 months before or during the first trimester of pregnancy (MINORE study). Poster presented at ECTRIMS 2021 (P655)."},{"issue":"5","key":"10.1016\/j.msard.2022.103792_bib0001","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s00415-012-6653-9","article-title":"Multiple sclerosis and pregnancy: therapeutic considerations","volume":"260","author":"Houtchens","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103792_bib0021","unstructured":"Introductory guide for standardised MedDRA queries (SMQs) Version 23.1. 2020."},{"issue":"12","key":"10.1016\/j.msard.2022.103792_bib0013","first-page":"423","article-title":"Ocrelizumab: its efficacy and safety in multiple sclerosis","volume":"66","author":"Juanatey","year":"2018","journal-title":"Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103792_bib0002","first-page":"125","article-title":"Recommendations for neurological, obstetrical and gynaecological care in women with multiple sclerosis: a statement by a working group convened by the section of multiple sclerosis and neuroimmunology of the polish neurological society","volume":"54","author":"Kalinowska","year":"2020","journal-title":"Neurol. Neurochir. Pol."},{"issue":"1","key":"10.1016\/j.msard.2022.103792_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy","volume":"104","author":"Kane","year":"2009","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.msard.2022.103792_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.msard.2022.103792_bib0019","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany","volume":"8","author":"K\u00fcmpfel","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"12","key":"10.1016\/j.msard.2022.103792_bib0032","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00002018-200427120-00003","article-title":"Data quality management in pharmacovigilance","volume":"27","author":"Lindquist","year":"2004","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.msard.2022.103792_bib0031","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00415-020-09913-1","article-title":"A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project","volume":"267","author":"Lopez-Leon","year":"2020","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103792_bib0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","article-title":"Evolution of maternofetal transport of immunoglobulins during human pregnancy","volume":"36","author":"Malek","year":"1996","journal-title":"Am. J. Reprod. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2022.103792_bib0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103792_bib0016","unstructured":"Ocrevus Summary of Product Characteristics, 2022."},{"key":"10.1016\/j.msard.2022.103792_bib0005","first-page":"21","article-title":"Indications for switching or stopping disease-modifying therapy for multiple sclerosis","author":"Olek","year":"2021","journal-title":"UpToDate"},{"key":"10.1016\/j.msard.2022.103792_bib0022","article-title":"Pregnancy outcomes in patients treated with ocrelizumab","author":"Oreja-Guevara","year":"2019","journal-title":"ECTRIMS"},{"key":"10.1016\/j.msard.2022.103792_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.msard.2022.103792_bib0009","unstructured":"Product Monograph Including Patient Medication Information Ocrevus. 2021. https:\/\/www.rochecanada.com\/PMs\/Ocrevus\/OCREVUS_PM_E.pdf."},{"issue":"6","key":"10.1016\/j.msard.2022.103792_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000903","article-title":"Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab","volume":"7","author":"Razaz","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2022.103792_bib0024","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/ror.0.0040081","article-title":"Dynamics of immunoglobulins at the feto-maternal interface","volume":"4","author":"Saji","year":"1999","journal-title":"Rev. Reprod."},{"issue":"2","key":"10.1016\/j.msard.2022.103792_bib0029","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/humupd\/4.2.185","article-title":"Clinical aspects of pregnancy after the age of 35 years: a review of the literature","volume":"4","author":"van Katwijk","year":"1998","journal-title":"Hum. Reprod. Update"},{"issue":"5","key":"10.1016\/j.msard.2022.103792_bib0004","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","article-title":"Pregnancy and multiple sclerosis: an update","volume":"33","author":"Varyt\u0117","year":"2021","journal-title":"Curr. Opin. Obstet. Gynecol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:59:13Z","timestamp":1761901153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822003066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"alternative-id":["S2211034822003066"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103792","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in Canada: A descriptive analysis of real-world data","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103792"}}